Search clinical trials for: Ertugliflozin

Total 45 results

Merck Sharp & Dohme LLC
Pfizer

Completed

Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)

Hypertension | Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC
Pfizer

Active, not recruiting

Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)

Type 2 Diabetes Mellitus

United States, Belgium, Canada, Colombia, Costa Rica, Dominican Republic, France, Guatemala, Hungary, Israel, Italy, Malaysia, Mauritius, Mexico, Philippines, Poland, Russian Federation, Saudi Arabia, Turkey, Ukraine, United Arab... and more
Merck Sharp & Dohme LLC
Pfizer

Completed

Study To Estimate The Relative Bioavailability of Ertugliflozin (PF-04971729, MK-8835) in Healthy Adult Participants (MK-8835-039)

Healthy
Merck Sharp & Dohme LLC
Pfizer

Completed

Effects of Once and Twice Daily Dosing Regimen of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-040)

Diabetes Mellitus, Type 2 | Adult
Merck Sharp & Dohme LLC
Pfizer

Completed

A Phase 1 Study of Ertugliflozin in Healthy Male Participants (MK-8835-020)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC
Pfizer

Completed

A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC
Pfizer

Completed

Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014)

Type 2 Diabetes Mellitus | Hepatic Impairment
Merck Sharp & Dohme LLC
Pfizer

Completed

A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)

Type 2 Diabetes Mellitus
Aga Khan University

Completed

Effectiveness of Nigella Sativa (Kalonji) Seed in Dyslipidemia

Hypertension | Diabetes Mellitus | Hypercholesterolemia | Metabolic Syndrome X

Pakistan
Merck Sharp & Dohme LLC
Pfizer

Completed

Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC
Pfizer

Completed

Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)

Type 2 Diabetes Mellitus
Amsterdam UMC, location VUmc

Completed

Renal Oxygenation, Oxygen Consumption and Hemodynamic Kinetics in Type 2 DIabetes: an Ertugliflozin Study. (ROCKIES)

Type 2 Diabetes Mellitus | Diabetic Nephropathy | Diabetic Kidney Disease | Renal Hypoxia | Renoprotection | SGLT2 Inhibitor | Ertugliflozin

Netherlands
Getz Pharma

Not yet recruiting

Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD (Ertu-NASH)

Body Weight Changes | Liver Fat | Tolerance | Liver Fibrosis | Glycemic Control | Waist Circumference
AdventHealth Translational Research Institute

Recruiting

Low-CArbohydrate Diet and SGLT2-INhibitOr to Achieve Moderate Ketosis in Healthy Volunteers (CASINO)

Ketones, Metabolism

United States
Medical University of Graz
Medical University of Vienna; Landesklinkum Wiener Neustadt; Klinik Ottakring; Medical... and other collaborators

Terminated

Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS (ERASe-Trial) - a Phase III Study (ERASE)

Implantable Cardioverter-Defibrillators | Heart Failure With Reduced Ejection Fraction | Cardiac Resynchronization Therapy | Heart Failure With Mid Range Ejection Fraction

Austria
University Hospitals Cleveland Medical Center

Terminated

Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure (EMMED-HF)

Diabetes Mellitus, Type 2 | Heart Failure, Diastolic

United States
National Cancer Institute (NCI)

Terminated

Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia

Leukemia, Adult T-Cell

United States
Merck Sharp & Dohme LLC
Pfizer

Completed

A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC
Pfizer

Completed

A Single Escalating Dose Study Of Ertugliflozin (PF-04971729, MK-8835) Under Fed and Fasted Conditons In Healthy Volunteers (MK-8835-036)

Type 2 Diabetes Mellitus
Amsterdam UMC, location VUmc
University of Colorado, Denver; Merck Sharp & Dohme LLC

Not yet recruiting

DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study (DESIGN)

Hypertension | Diabetes Mellitus | Diabetic Kidney Disease
Merck Sharp & Dohme LLC
Pfizer

Completed

A Multiple Dose Study Of Ertugliflozin (PF-04971729, MK-8835) In Otherwise Healthy Overweight And Obese Volunteers (MK-8835-037)

Healthy Volunteer
Kiyuk Chang
Seoul St. Mary's Hospital; Pusan National University Hospital; Korea University... and other collaborators

Recruiting

SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients With Acute Myocardial Infarction, a Prospective, Multi-center Registry Study (RECORD-AMI)

Myocardial Infarction | Diabetes Mellitus, Type 2

Korea, Republic of
Merck Sharp & Dohme LLC
Pfizer

Completed

Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC
Pfizer

Completed

Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC
Pfizer

Completed

A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).

Type 2 Diabetes Mellitus
Bristol-Myers Squibb

Completed

A Bioequivalence Study of Daclatasvir Tablets and Bioavailability Studies of Daclatasvir and Asunaprevir

Hepatitis C Infection
Soo Lim
MSD Korea Ltd.

Completed

Effect of Ertugliflozin on Cardiac Function in Diabetes (ERTU-GLS)

Heart Failure | Type2 Diabetes

Korea, Republic of
Merck Sharp & Dohme LLC
Pfizer

Completed

Evaluation of Pharmacokinetics, Safety, And Tolerability Of Ertugliflozin (PF-04971729, MK-8835) In Japanese And Western Healthy Participants (MK-8835-041)

Diabetes Mellitus, Type 2
Asan Medical Center
Merck Sharp & Dohme LLC

Completed

Ertugliflozin for Functional Mitral Regurgitation (EFFORT)

Mitral Valve Insufficiency | Left Ventricular Systolic Dysfunction

Korea, Republic of
Yonsei University

Unknown

Validation of ERTugliflozin for Inhibiting Cardiac Fibrosis Using Cardiac MRI and Laboratory Parameters in Korean Heart Failure Patients With Nonischemic Cardiomyopathy(VERTICAL)

Heart Failure With Nonischemic Cardiomyopathy

Korea, Republic of
Merck Sharp & Dohme LLC
Pfizer

Completed

A Radiolabeled Mass Balance Study of [14C]-Ertugliflozin (PF04971729, MK-8835) In Healthy Male Participants (MK-8835-038)

Type 2 Diabetes Mellitus (T2DM)
LMC Diabetes & Endocrinology Ltd.
Merck Sharp & Dohme LLC; Syreon Corporation

Withdrawn

Approaches To Therapy Escalation In T2D (ATTACC)

Type2 Diabetes
Icahn School of Medicine at Mount Sinai

Recruiting

ERTU-SODIUM: Study on the Effects of Ertugliflozin on Sodium Storage, Interstitial Volume, and Plasma Volume in HFrEF (ERTU-SODIUM)

Heart Failure With Reduced Ejection Fraction | Congestion

United States
University Health Network, Toronto
Merck Sharp & Dohme LLC; University Medical Center Groningen; University of Toronto and other collaborators

Completed

ERtugliflozin triAl in DIabetes With Preserved or Reduced ejeCtion FrAcTion mEchanistic Evaluation in Heart Failure (ERADICATE-HF)

Heart Failure | Type 2 Diabetes Mellitus

Netherlands, Canada
Merck Sharp & Dohme LLC
Pfizer

Completed

Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009)

Type 2 Diabetes Mellitus | Renal Impairment
Stanford University
Merck Sharp & Dohme LLC

Active, not recruiting

Ertugliflozin: Cardioprotective Effects on Epicardial Fat

Cardiovascular Diseases | Atherosclerosis | Insulin Resistance | Type 2 Diabetes

United States
Merck Sharp & Dohme LLC
Pfizer

Completed

Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC
Pfizer

Completed

Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)

Type 2 Diabetes Mellitus
Yale University
Merck Sharp & Dohme LLC

Recruiting

Ertugliflozin in Chronic Heart Failure

Heart Failure

United States
University of Utah
Leadiant Biosciences, Inc.; Families of Spinal Muscular Atrophy

Completed

CARNIVAL Type I: Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy (SMA) Type I

Spinal Muscular Atrophy Type I

United States, Canada, Germany
Matthew Neal MD
National Heart, Lung, and Blood Institute (NHLBI)

Active, not recruiting

Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE (ACTIV-4A)

Covid19

United States, Spain, Brazil, Italy
Brigham and Women's Hospital
Patient-Centered Outcomes Research Institute; McGill University; VA Boston Healthcare...

Active, not recruiting

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study (CER-4-T2D)

Type2 Diabetes | Renal Disease | Cardiovascular Events

United States
Cedars-Sinai Medical Center
Merck Sharp & Dohme LLC

Withdrawn

Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes. (Ertugliflozin)

Hypertension | Diabetes Mellitus, Type 2

United States
Columbia University

Withdrawn

Denileukine Diftitox for Relapsed ALCL

Anaplastic Large-Cell Lymphoma

United States
University of California, San Francisco

Completed

Effects of Gastric pH on the Pharmacokinetics of Atazanavir

Healthy

United States

3

Subscribe